ResearcherCentral South UniversityNo recent work listed
Xiongying Miao
Matched on OpenAlex author ID A5100548762. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper
Papers 7
- Integrating Network Pharmacology and Experimental Verification to Explore the Mechanism of Effect of Zuojin Pills in Pancreatic Cancer Treatment. First author DOI 10.2147/dddt.s323360↗
- Downregulation of METTL14 increases apoptosis and autophagy induced by cisplatin in pancreatic cancer cells. Co-author DOI 10.1016/j.biocel.2020.105731↗
- Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis. Co-author DOI 10.1186/s12957-016-0813-9↗
- Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.3233/cbm-160655↗
- The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13277-015-3752-0↗
- Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma. Co-author DOI 10.3233/cbm-150515↗
- Expression of DNA-repair proteins and their significance in pancreatic cancer and non-cancerous pancreatic tissues of Sprague-Dawley rats. Last author DOI 10.1186/1477-7819-12-32↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Leping Yang · 4 shared papers, 2014–2020 · strength 0.30
- Paper Downregulation of METTL14 increases apoptosis and autophagy induced by cisplatin in pancreatic cancer cells. DOI 10.1016/j.biocel.2020.105731↗
- Paper Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma. DOI 10.3233/cbm-160655↗
- Paper Expression of DNA-repair proteins and their significance in pancreatic cancer and non-cancerous pancreatic tissues of S… DOI 10.1186/1477-7819-12-32↗
- Fanhua Kong · 2 shared papers, 2020–2021 · strength 0.27
- Paper Integrating Network Pharmacology and Experimental Verification to Explore the Mechanism of Effect of Zuojin Pills in Pa… DOI 10.2147/dddt.s323360↗
- Paper Downregulation of METTL14 increases apoptosis and autophagy induced by cisplatin in pancreatic cancer cells. DOI 10.1016/j.biocel.2020.105731↗
- Qiong Zou · 3 shared papers, 2015–2016 · strength 0.17
- Paper Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma. DOI 10.3233/cbm-160655↗
- Paper The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma. DOI 10.1007/s13277-015-3752-0↗
- Paper Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the p… DOI 10.3233/cbm-150515↗
- Yuan Yuan Ma · 3 shared papers, 2015–2016 · strength 0.17
- Paper Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma. DOI 10.3233/cbm-160655↗
- Paper The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma. DOI 10.1007/s13277-015-3752-0↗
- Paper Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the p… DOI 10.3233/cbm-150515↗
- Kunpeng Wang · 1 shared paper, 2021 · strength 0.15
- Yanwen Zheng · 1 shared paper, 2021 · strength 0.15
- Jinggang Mo · 1 shared paper, 2021 · strength 0.15
- Xuyang Hou · 1 shared paper, 2020 · strength 0.12
- Jun He · 1 shared paper, 2020 · strength 0.12
- Yan Zhou · 1 shared paper, 2020 · strength 0.12
- Guoqing Ouyang · 1 shared paper, 2016 · strength 0.07
- Yu Wen · 1 shared paper, 2016 · strength 0.07
- Hongliang Yao · 1 shared paper, 2016 · strength 0.06
- Xingguo Tan · 1 shared paper, 2014 · strength 0.06
- Chun Liu · 1 shared paper, 2015 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.